Algorae Pharmaceuticals Ltd (ASX:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
48

Recommended

Shares drop 17% after guidance is revised but we still see value.

Shane Ponraj | 09 January 2025

Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.

Joseph Taylor | 09 January 2025

These undervalued stocks with reliable dividends are worth considering.

Susan Dziubinski | 08 January 2025

Index	Last price	Change	% Change
All Ordinaries	8,543.70	34.10	-0.40%
CAC 40	7,431.04	59.24	-0.79%
DAX 40	20,214.79	102.31	-0.50%
Dow JONES (US)	41,938.45	696.75	-1.63%
FTSE 100	8,248.49	71.20	-0.86%
HKSE	19,064.29	176.60	-0.92%
NASDAQ	19,161.63	317.25	-1.63%
Nikkei 225	39,190.40	414.69	-1.05%
NZX 50 Index	12,895.98	47.76	-0.37%
S&P 500	5,827.04	91.21	-1.54%
S&P/ASX 200	8,294.10	35.10	-0.42%
SSE Composite Index	3,168.52	42.87	-1.33%